We observed that intravenous administration of miR-34a nanocells reduced both cMet and phosphorylated Akt levels in orthotopically implanted glioblastoma tumors to a similar extent as in vitro transfection (Fig. 6a–c). The gene discussed is AKT1; the disease is glioblastoma.